Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
11,194,065
-
Shares change
-
+521,069
-
Total reported value, excl. options
-
$115,764,000
-
Value change
-
+$5,400,505
-
Number of buys
-
11
-
Number of sells
-
-11
-
Price
-
$10.35
Significant Holders of MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) as of Q2 2021
47 filings reported holding HLXA - MOONLAKE IMMUNOTHERAPEUTICS - COM as of Q2 2021.
MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11,194,065 shares
.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (1,011,589 shares), PRICE T ROWE ASSOCIATES INC /MD/ (756,303 shares), RTW INVESTMENTS, LP (750,000 shares), BlackRock Inc. (747,863 shares), RA CAPITAL MANAGEMENT, L.P. (700,000 shares), CITADEL ADVISORS LLC (691,731 shares), WELLINGTON MANAGEMENT GROUP LLP (516,296 shares), Ghost Tree Capital, LLC (500,000 shares), STALEY CAPITAL ADVISERS INC (500,000 shares), and Cormorant Asset Management, LP (430,000 shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.